Sage Therapeutics Meets Primary Endpoint in Huntington’s Disease Trial

Sage Therapeutics (Nasdaq: SAGE) has announced positive topline results from its Phase 2 SURVEYOR study evaluating dalzanemdor (SAGE-718) as a treatment for Huntington’s Disease. The study met its primary endpoint, demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo.

Laura Gault, Chief Medical Officer, Sage Therapeutics, said, “The findings from the SURVEYOR Study highlight the extent of cognitive impairment associated with HD and enhance our collective understanding of this devastating disease. This finding further underscores the importance of developing treatments that can address this critical unmet need for people living with HD.”

Sage’s study, which enrolled 40 participants with HD and 29 healthy volunteers, demonstrated the HD-CAB composite score at baseline between the two groups of participants, further underscoring the extent of cognitive impairment associated with HD and the significant unmet need for treatment options. The study was not designed or powered to demonstrate a statistically significant difference between dalzanemdor and placebo.

In the second part of the study, participants with HD were randomly assigned to receive dalzanemdor or placebo for a 28-day treatment period. Dalzanemdor was generally well-tolerated with no new safety signals observed.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

 

Share This Article

 

About the Author

Sage Therapeutics Meets Primary Endpoint in Huntington’s Disease Trial

Catie Corcoran

Biotech Editor